$OSCR

Blackley Richard Scott sold $695K of OSCR

Blackley Richard Scott (Chief Financial Officer) sold 31,683 shares of Oscar Health, Inc. (OSCR) at an average of $21.94 ($21.74–$22.45, $0.70M total) across 2 trades on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blackley Richard Scott
Published Jun 4, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Bearish
medium confidence
Mentioned
$OSCR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRBearishLow
01

Why it matters

The transaction provides fresh data on insider sentiment and may influence short‑term price dynamics.

02

Market read

First‑report insider sale; modest size but notable due to CFO involvement.

03

What to watch

The CFO may be diversifying holdings; the company has not disclosed any operational issues.

Relevance 4/10Novelty 5/10Timing: after-market today

Background

SEC Form 4 filing discloses an insider transaction by Oscar Health's CFO.

Company-level read

Ticker impact

$OSCRBearishMedium confidence
Context

CFO Blackley Richard Scott sold 31,683 shares for $695K via a 10b5-1 plan, reducing his stake to 1,074,977 shares.

Expected impact

likely pressure as the market prices in the CFO's sell-off

Evidence & confidence

A $695K sale by the CFO is a material insider transaction that can be interpreted as a negative signal, especially given the recent price range.

Market effects

Minimal impact on the health‑tech sector; the sale is company‑specific.

No broader regional effect.

Limited to Oscar Health investors.

Counterpoint

The sale could be a routine portfolio rebalancing under a pre‑arranged 10b5‑1 plan, not a negative signal.

Key entities

  • Oscar Health, Inc.

    US‑listed health‑tech insurer (ticker OSCR).

  • Blackley Richard Scott

    Chief Financial Officer of Oscar Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OSCRHighAI 8/10

OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises

Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.

$OSCRHighAI 8/10

Oscar Health boosts 2026 earnings outlook, affirms revenue

Oscar Health (OSCR) updated its 2026 earnings outlook, lowering its Medical Loss Ratio to 81.0%-82.0% and raising earnings from operations to $600M-$800M. The company reaffirmed revenue guidance of $18.7B-$19.0B and maintained SG&A expense ratio targets. The updates will be discussed at its 2026 Investor Day on September 16, 2026.

$OSCRHighAI 8/10

Oscar Health raises FY26 earnings guidance by $100 million

Oscar Health (OSCR) raised its 2026 earnings guidance by $100 million, citing improved cost controls. The company expects earnings from operations to range from $600 million to $800 million, with a medical loss ratio of 81.0% to 82.0%. Total revenue guidance remains unchanged at $18.7 billion to $19.0 billion. The stock has gained 85.57% over the past year, reaching a 52-week high of $27.59.